Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines developer for neuromuscular and cardiac diseases, has announced its participation in two upcoming investor conferences. Bo Cumbo, President and CEO, will be involved in both events:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY: Cumbo will participate in a fireside chat on September 10, 2024, at 9:30 am ET.
2. Baird 2024 Global Healthcare Conference in New York, NY: Cumbo will present on September 11, 2024, at 12:50 pm ET.
A live webcast of the H.C. Wainwright fireside chat will be available on the company's website, with a replay archived for 30 days. Institutional investors can arrange meetings with management through their H.C. Wainwright or Baird representatives.
Solid Biosciences (NASDAQ: SLDB) reported Q2 2024 financial results and provided business updates. Key highlights include:
- Patient dosing in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for Duchenne muscular dystrophy was well-tolerated, with initial data expected Q4 2024.
- Plans to expand trial sites in the U.S., Canada, and Europe, with accelerated production of SGT-003 GMP batches.
- Targeting 3-4 IND submissions by end of 2026, including SGT-501 for CPVT in 1H 2025.
- Q2 2024 ended with $190.3 million in cash and equivalents, providing runway into 2026.
- Q2 2024 net loss was $25.1 million, or $0.61 per share.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has announced equity grants to newly hired employees. The company granted 86,665 restricted stock units (RSUs) to four new hires, vesting in four equal annual installments. Additionally, one employee received an option to purchase 100,000 shares of common stock at $8.64 per share, vesting over four years. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4), serving as inducements for employment.
Solid Biosciences has announced the grant of 11,847 restricted stock units (RSUs) to a new employee. The RSUs will vest over four years, with equal installments on each anniversary of the grant date. This grant is part of the 2024 Inducement Stock Incentive Plan and aims to encourage the new hire's long-term commitment to the company. The grant complies with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) announced its inclusion in the Russell 3000® Index, effective July 1, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks, ranking them by market capitalization. Membership in the Russell 3000® Index grants automatic inclusion in the Russell 1000® or Russell 2000® Index, and relevant growth and value style indexes. The inclusion reflects Solid Biosciences' progress in genetic medicine for neuromuscular and cardiac diseases. As of December 2023, approximately $10.5 trillion assets are benchmarked against Russell US indexes.
Solid Biosciences, a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, announced the issuance of 30,949 restricted stock units (RSUs) to four newly hired employees. These RSUs will vest in equal installments over four years, contingent on continued service. The grants were made under the 2024 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences reported Q1 2024 financial results and business updates, highlighting the Rare Pediatric Disease and Orphan Drug Designation for its Duchenne muscular dystrophy gene therapy candidate, SGT-003. The company plans to begin dosing in a Phase 1/2 trial in Q2 2024 with initial data expected by Q4 2024. Solid has entered a non-exclusive licensing agreement for its AAV-SLB101 capsid and maintains a strong cash position of $206.1 million, providing runway into 2026. R&D expenses decreased to $18.9 million due to prioritization of SGT-003, while net loss reduced to $24.3 million. Solid is advancing its diversified pipeline, including SGT-501 for CPVT, expected to file an IND in Q1 2025.
Solid Biosciences Inc. will present at the ASGCT 2024 Annual Meeting, showcasing advancements in AAV manufacturing, vector biology, and non-clinical data of their lead SGT-003 program. The presentations aim to highlight the company's commitment to developing genetic medicines for neuromuscular and cardiac diseases.
Solid Biosciences Inc. announced the issuance of 38,508 restricted stock units to two new employees under the 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years subject to continued service with the company, in line with Nasdaq Listing Rule 5635(c)(4).
Summary not available.